Interventional Oncology Market Size and Growth
The global interventional oncology market size was valued at USD 6.25 billion in 2024 and is anticipated to reach around USD 16.67 billion by 2034, growing at a CAGR of 10.31% from 2025 to 2034.
Interventional Oncology Market Key Takeaways
- North America dominated the interventional oncology market in 2024.
- Asia Pacific is expected to grow at the fastest rate during the forecast period.
- By technique, ablation therapies are dominating the market in 2024.
- By technique, embolization therapies are the fastest growing type as of this year.
- By procedure, tumor ablation is the most dominantly used procedure.
- By procedure, vascular intervention is the fastest growing segment.
- By application, liver cancer remains the largest and most dominant application segment.
- By application, lung cancer is the fastest growing segment as of 2024.
- By end user, hospitals dominated the segment.
- By end-user, specialty clinics are the fastest growing segment.
How is the Interventional Oncology Market Evolving?
The interventional oncology market is evolving rapidly, shaped by a growing demand for precision-based medicine and minimally invasive cancer treatments. This field merges advanced imaging techniques with targeted therapies and is gaining momentum as healthcare providers and patients seek alternatives to traditional surgery and systemic chemotherapy. The appeal lies in its ability to treat tumors in a direct manner, often with fewer side effects and shorter recovery times, making it especially valuable for patients who are not willing for conventional procedures. Technological innovation is another major driver of change.
New tools and techniques such as image-guided ablation and embolization are becoming more refined, allowing oncologists to treat tumors with a much greater accuracy and safety. These procedures are increasingly being integrated into multidisciplinary cancer care, with interventional oncologists working alongside medical and surgical teams to provide treatments catered to the individual patient’s needs. There's also a shift towards outpatient care as many interventional oncology procedures can now be performed in ambulatory settings, thus reducing hospital stays and healthcare costs.
As more clinicians are being trained to keep up with these techniques along with patients becoming more informed about their options helps foster a more proactive approach to cancer management, where early intervention and personalized care are a priority. As the healthcare landscape continues to introduce new innovations and patient-centered models in the market, interventional oncology is set to play a vital role in the future of cancer treatment, one that is defined by precision, adaptability, and hope.
What are the Key Trends in the Interventional Oncology Market?
- Cutting edge researchers introduced laser profiled electrode catheters that enable bioelectric tracking inside vessels, reducing the dependency on X-ray fluoroscopy and radiation exposure in interventional procedures.
- New AI driven techniques now use real time image fusion that combine modalities, ultrasound, hyperspectral imaging and elastography in order to support more accurate and fast cancer diagnosis, helping in rapid procedural decision making.
- Labs are integrating diagnosis aspects with therapy by combining imaging with temperature monitoring to create a seamless, image guided treatment control.
- ECT (Electrochemotherapy) is being experimented on for prostate cancer diagnosis. This method uses electric pulses to enhance chemotherapy uptake in tumors.
- There has recently been significant development in the natural language processing space, with chatbots like ChatGPT (OpenAI) and Bard (Google) becoming popular in this domain. These LLMs may be useful for patient education on interventional procedures, producing patient-specific explanations and may serve as decision-making tools for clinicians.
Impact of AI on Interventional Oncology Market:
Artificial intelligence is reshaping the landscape of the interventional oncology market by enhancing precision, efficiency, and personalization across the entire plethora of treatment. AI algorithms are now being used to automatically detect and segment tumors as well as the surrounding organs in imaging scans, streamlining pre-procedural planning and reducing human error. During procedures, AI can improve image quality in real time, helping clinicians navigate complex anatomy with a greater confidence.
It can also analyze massive amounts of data like genomic profiles and protein structures in order to predict how a patient might respond to a particular mode of treatment. LLM models are also gaining popularity, taking on the role of a reliable ally as they have produced near-physician results in tumor board recommendations. They may also facilitate time-consuming tasks for IO practitioners and condense large data bases, potentially providing clinical decision support in time-sensitive situations.
AI has also made its way into post-treatment practices, machine learning models are capable of predicting patient outcomes and detecting early signs of recurrence, allowing for a more proactive follow-up care. Radiomics is often integrated with AI in order to uncover patterns that are invisible to the human eye, offering deeper insights into tumor behavior.
This is particularly important in the oncology field, where slight changes and timing can alter patient outcomes. As research progresses and clinical adoption grows, AI is set to become an indispensable tool in interventional oncology, assisting in making more informed decisions and ultimately giving patients a chance for a long, healthy life.
Interventional Oncology Market Report Scope
Market Dynamics
Driver
Rising Incidence of Cancer and Preference for Targeted Therapies
A key factor which is driving the growth of the interventional oncology market is the rising number of cancer cases worldwide, along with the clear clinical and cost benefits of targeted, localized treatments. As cancer rates continue to climb world wide, especially in types like liver, lung, breast and colorectal, healthcare systems are pressurized to find effective and efficient ways to manage or treat the disease. Interventional oncology is emerging as a valuable solution as it uses techniques such as Transarterial Chemoembolization (TACE) and Radiofrequency Ablation (RFA) to treat tumors directly at the site, often with fewer side effects than compared to traditional chemotherapy or radiation.
TACE is also now widely recognized as a leading treatment for certain stages of liver cancer. These procedures also offer hope to patients who cannot undergo surgery, thus broadening access to specialized care. As more clinical studies confirm the effectiveness of these methods across various cancer types, they are being integrated into official treatment guidelines, helping to accelerate their use in mainstream medical practice.
Restraint
High Cost and Infrastructure Demands
While interventional oncology holds great promise for improving cancer care, it does face several challenges. One of the biggest hurdles is the high cost of equipment and infrastructure. Establishing an interventional oncology unit requires advanced imaging systems like CT, MRI, fluoroscopy and angiography suites, which demand significant financial investments. On top of that, the procedures often rely on disposable tools such as ablation probes and catheters, adding to the ongoing expenses, which is especially difficult for hospitals operating in resource-limited settings. Another barrier is the need for highly trained specialists. These procedures need a a coordinated and highly skilled team that includes interventional radiologists, anesthesiologists, and nurses. This level of expertise is not always available in rural or underserved areas, making it harder to expand access.
Opportunity
Advancements in Image-guided Nanotechnology and Targeted Drug Delivery
One of the most revolutionary developments in interventional oncology is its integration with nanotechnology and advanced drug delivery systems. New materials like injectable hydrogels, nanoparticles and drug-eluting beads are changing the way cancer drugs reach atumors. These innovations allow for a precise, controlled release of medication directly at the tumor site, which helps toa improve treatment effectiveness while reducing side effects throughout the body. At the same time, imaging technologies are becoming more sophisticated.
Tools like MRI thermometry and contrast-enhanced ultrasound now enable doctors to track treatment progress in real time. Some companies are even creating agents that serve dual purposes, acting both as imaging contrast and carriers for therapy. Such medical breakthroughs not only improve accuracy but also make it possible to treat tumors that were previously considered too risky or difficult to reach. With ongoing clinical trials, experiments, investments and growing collaborations between pharmaceutical and medical technology companies, these innovations are now moving closer to becoming widely available in clinical practice.
Interventional Oncology Market By Technique Insights
Ablation therapies are dominating the market in 2024. This is because they are minimally invasive in nature, have the ability to destroy tumors precisely and are suitable for patients who cannot undergo surgical procedures. Radiofrequency and microwave ablation therapies are the most popular and are widely adopted for liver, lung and kidney cancers. The advantage of this segment lies in its shorter recovery time, reduced hospital stay and repeatability without any major side effects, making it a practical choice for tumors that are recurrent. They can also be perfomed at an outpatient basis, making it patient friendly as well as cost effective.
Embolization therapies are the fastest growing type as of this year. TACE and Y-90 are gaining traction in particular as they enable drug targeted radiation delivery directly on the tumor site while keeping the healthy tissue intact. This reduces systemic toxicity and greatly enhances therapeutic outcomes, making it a valuable option for patients who opt out of surgery. Advances in novel embolic agents as well as drug eluting beads are fueling this segment even more. Other segments such as biopsy techniques and image guided procedures while not so dominant, are still contributing in diagnosis and treatment planning with the help of AI guidance, which gives precision, reduced complications and ensure that the treatment benefits the patient in the best way.
Interventional Oncology Market By Procedure Insights
Tumor ablation is the most dominantly used procedure due to its growing success in managing both, primary and metastatic tumors. This type of procedure spares the healthy cells and tissues while only targeting the affected area, making it minimally invasive, especially when it comes to localized types of cancers. Moreover, it has a strong clinical validation for hepatocellular carcinoma and other solid tumors, leading to its widespread adoption.
Vascular intervention is the fastest growing segment this year. Treatments like TACE, SIRT etc. have revolutionized cancer care, making this segment popular. Their lead is due to their ability to access the tumor site with the help of vasculature, which helps to improve efficacy. This type of procedure is mainly used in cases of inoperable cancers such as the liver, bone, renal or lung tumors. Unlike systemic chemotherapy, this procedure delivers drugs directly to the tumor using blood vessels, maximizing its effectiveness and minimizing side effects. Another segment that remains significant is tumor biopsy, which is an important part for diagnosis and staging. Palliative care procedures are also slowly gaining recognition as they are a part of comprehensive cancer management. These interventions include pain alleviation, reducing tumor burden and improving quality of life.
Interventional Oncology Market By Application Insights
Liver cancer remains the largest and most dominant application segment, as IO techniques like TACE and RFA are considered the main forms of treatment. This is because there is a global rise in HCC (Hepatocellular carcinoma) and a majority of liver cancer patients cannot be eligible for surgical procedures. It is observed that liver cancers respond well to minimally invasive types of treatment, making them the cornerstone of oncology clinical practices.
Lung cancer is the fastest growing segment as of 2024. Image guided ablation and broncho scopic interventions are being widely adopted to provide quick and effective treatment, especially during small, early stage tumors. As image guiding technologies and microwave ablation techniques improve, such interventional procedures are expected to grow at a rapid pace. Other segments such as Kidney cancer, Prostate cancer and breast cancer represent stable yet steadily expanding segments. There is a growing interest in experiments and technologies such as irreversible electroporation and high intensity focused ultrasound, encouraging wide spread adoption in the near future.
Interventional Oncology Market By End Use Insights
Hospitals dominated the end-user segment due to their robust infrastructure, availability of resources and a multidisciplinary expertise which is required for such procedures. Hospitals are well equipped with CT scans, MRI, cone-beam scanners and hybrid operating suites, creating a cohesive, multidisciplinary cancer care team. Interventional procedures often require advanced facilities, support and monitoring, all of which hospitals provide.
Specialty clinics are the fastest growing segment in 2024 driven by the trend towards outpatient, minimally invasive procedures. Clinics dedicated to interventional oncology are being set up in urban areas where the demand for cost effective and patient friendly care is rising.
These specialty clinics are popular as they offer less waiting time and personalized care at reduced overall treatment costs. Technological advances such as portable systems and compact imaging solutions are further pushing this segment forward.
Interventional Oncology Market By Regional Insights
Why does North America lead the Interventional Oncology Market?
North America is dominating the global interventional oncology market, largely due to its advanced healthcare systems, strong technological capabilities and high rates of cancer. The region performs a significant number of procedures, supported by the availability of skilled radiologists and insurance coverage for treatments like ablation and embolization. Renowned hospitals such as MD Anderson Cancer Center, Mayo Clinic, and Cleveland Clinic have also developed specialized programs that offer cutting-edge care and attract patients from around the world. In addition to their clinical prowess, the region is also actively involved in heavy research and development, hosting numerous clinical trials that are focused on innovative technologies. These efforts are further supported by collaborations and investments between academic institutions, medical device companies and biotech firms, helping North America maintain its leadership in this field.
What are the Advancements in the Asia-Pacific?
The Asia-Pacific region is emerging as the fastest-growing market in interventional oncology, driven by a rising number of cancer cases, better access to healthcare, improved living standards and rapid development of medical infrastructure. Countries such as China, India, South Korea, and Japan are making significant investments in order to modernize and enhance their oncology services. As a result, interventional oncology is gaining popularity as a more affordable and less invasive treatment option compared to other traditional methods. With increasing public awareness and improvements in reimbursement policies, the adoption of interventional oncology is expected to keep growing substantially across the region in the upcoming years, highlighting a patient centered shift.
Country Level Analysis
The interventional oncology sector is gaining serious traction in the United States, particularly due to their mature and technology driven environment. Academic centers, hospitals and healthcare research centers remain practical engines, boosting innovation and delivery. Clinical practices in the U.S champion innovations such as MRI guided ablations and image fusion techniques while simultaneously updating themselves with the latest technological advancements. These institutions also build strong clinical training frameworks to ensure that the patient receives the highest quality of care and treatment. What makes the U.S stand out the most is its rapid adoption and acceptance of technological advancements. On the technology front, Stryker company’s partnership with Care.
AI has bought quite a lot of change, offering smarter, more efficient AI driven platforms that improve patient experience. Additionally, Profound Medicals have also partnered up with Siemens Healthineers in order to roll out MRI guided prostate systems, highlighting how technology and treatment are being seamlessly integrated in the healthcare domain. These actions show us how the country is moving towards a more value based care, where providers are seeking options that reduce hospital stays, lower complications and make the patient feel secure.
Interventional Oncology Market Top Key Companies:
- Boston Scientific Corporation
- Johnson & Johnson
- Baxter International Inc.
- Dickinson and Company
- AngioDynamics Inc.
- Terumo Corporation
- Siemens Healthineers
- GE Healthcare
- Teleflex Incorporated
- Cook Medical
- Stryker Corporation
- Profound Medical
Interventional Oncology Market Recent Developments
- In August 2025, the Society of Interventional Oncology (SIO) proudly announced that the Washington University School of Medicine in St. Louis, MO, USA, has been the first site approved and activated for enrollment in the society's second clinical trial of TRIBUTE (Trial of Symptomatic, High-Risk Bone Metastases Treated with Percutaneous Ablation and Palliative Radiation Therapy). This will be the first multi-center study to evaluate real-world outcomes in adult patients treated with both percutaneous ablation and palliative radiation therapy (RT) for symptomatic, high-risk metastatic bone lesions.
- In August 2025, Delcath Systems (NASDAQ: DCTH) which is an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announced that the first patient has been dosed at the City of Hope National Medical Center in its global Phase 2 Clinical Trial evaluating HEPZATO. The Phase 2 trial will evaluate the safety and efficacy of HEPZATO in combination with trifluridine-tipiracil and bevacizumab compared to trifluridine-tipiracil and bevacizumab alone in patients with liver-dominant mCRC receiving third-line treatment. This study will be conducted at more than 20 sites across the United States.
Interventional Oncology Market Report Segmentation
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the Interventional Oncology market.
By Technique
- Ablation Therapies
- Radiofrequency Ablation (RFA)
- Microwave Ablation (MWA)
- Cryoablation
- Laser Ablation
- Irreversible Electroporation (IRE)
- Embolization Therapies
- Transarterial Chemoembolization (TACE)
- Transarterial Radioembolization (TARE)
- Biopsy Techniques
- Core Needle Biopsy
- Fine Needle Aspiration (FNA)
- Targeted Therapy Delivery Systems
- Drug-Eluting Beads
- Radioembolization
- Drug-Eluting Stents
- Injectable Hydrogels and Nanoparticles
- Other Targeted Therapy Systems
- Image-Guided Procedures
- Ultrasound Guidance
- CT Scan Guidance
- MRI Guidance
- Fluoroscopy Guidance
By Procedure
- Tumor Ablation
- Tumor Biopsy
- Vascular Interventions
- Palliative Care
By Application
- Liver Cancer
- Lung Cancer
- Kidney Cancer
- Prostate Cancer
- Breast Cancer
- Other Cancer
By End Use
- Hospitals
- Specialty Clinics
- Others
By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa (MEA)
Request Customization
Get a Sample
Get a Sample
Request Customization